Navigation Links
Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
Date:5/17/2009

egion and professor in the Departments of Medicine and Microbiology-Infectious Diseases, University of Calgary. "These findings indicate that fidaxomicin offers both highly effective but more selective therapy that is less damaging to the normal intestinal bacteria that protect against recurrence of CDI."

Additional findings also presented for the first time include a subgroup analysis of clinical cure and recurrence rates for fidaxomicin compared to Vancocin, as well as baseline demographic and disease characteristics. Clinical cure rates for fidaxomicin and Vancocin were similar in each of the following subgroups: patient status (in-patient/out-patient), age (under/over 65) and strain type (BI/NAP1/027). Most notably, fidaxomicin showed a reduction across several subgroups in recurrence rates compared to Vancocin in both out-patient and in-patient settings, as well as in patients both over and under the age of 65. The recurrence rates in the BI/NAP1/027 subgroup were similar between fidaxomicin and Vancocin.

    Per Protocol                          Fidaxomicin     Vancocin(R) capsules
    (microbiologically evaluable)         (200mg bid)         (125mg qid)

    Recurrence Rates by Subgroup
    Patient Status
      In-patient                          17.9% (19/106)      26.1% (29/111)
      Out-patient                          8.6% (9/105)       21.8% (24/110)

    Age
      < 65                                 9.5% (12/126)      18.6% (22/118)
      >/= 65                              18.8% (16/85)       30.1% (31/103)

    Strain Type
     BI (NAP1/027)                        25.0% (11/44)       24.1% (13/54)
    Overall                               13.3% (28/211)      24.0% (53/221)

Baseline demographic and disease characteristics of study participants were similar between the fidaxomicin and Vancocin arms. The BI/NAP1/027 hyper virulent strain of C. difficile'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BEVERLY HILLS, Calif. , Jan. 14, 2014 ... , offers Los Angeles a premier ... Duality laser and a $99 treatment special. Dr. Brandeis, focus ... medical technology and offering expert medical advice to all patients. ... a dramatic increase in the presence of tattoo regret and ...
(Date:1/14/2014)... 2014 Animal Emergency Critical Care, a LifeCentre partner practice, ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a ... Dr. Cole Taylor , are avid scuba divers. "As altitude ... when air is thin," states Dr Barnes. She goes on to ...
(Date:1/14/2014)... --  Oligomerix, Inc. , a privately held company ... Alzheimer,s disease (AD) and related neurodegenerative disorders, announced ... Valhalla, NY as of ... additional laboratory space at New York Medical College. ... development of small molecule drugs aimed specifically at ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... EORTC 40983 (EPOC),Intergroup Study Results, CHICAGO, June ... phase III EORTC 40983 Intergroup study, or ... peri-operative (pre and post,surgery) FOLFOX4 (Eloxatin(R) (oxaliplatin ... for colon cancer,5-fluorouracil/leucovorin (5-FU/LV)) given to patients ...
... Phase II Study Results Presented at Society ... 04, 2007 /PRNewswire-FirstCall/ --,Immunomedics, Inc. , a ... treat cancer and other serious,diseases, today announced ... with the radioisotope,iodine-131, was found to be ...
Cached Medicine Technology:The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 2The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 3The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 4The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 5The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 6The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 7The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 8The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 9Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... a healthy weight. The study shows a higher body mass ... of life in older age. ,Since the beginning ... life expectancy. Meanwhile, the prevalence of overweight and obesity among ... an impact on individuals as they age? Researchers conducted a ...
... the 1960s, surgeons experimented by transplanting chimpanzee organs into humans ... received a baboon heart and survived 20 days. // Since ... source for organs, tissues and cells to treat various diseases, ... the controversy surrounding cross-species transplant -- also known as xenotransplantation. ...
... because lifestyle changes and medication can prevent or delay the ... is used to identify high-risk individuals for diabetes, but the ... cluster of risk //factors known as metabolic syndrome is able ... ,Metabolic syndrome has been shown to lead to ...
... problem worldwide. Both osteoarthritis and rheumatoid arthritis cause joint ... for arthritis and no effective treatment to repair damaged ... doctors towards a drug to prevent the onset of ... enzyme that play a pivotal role in the onset ...
... New research finds that women who change partners between the births ... babies with a low birth weight than women who have the ... likely to die within the first year of life. The results ... age and education, the interval between births, and the decades of ...
... pain, the right mattress can make a difference. //Three-quarters of ... but a new study says they could be wrong. The ... back pain. ,Physicians often get frustrated when patients ... lower back pain. Few studies have been done on this ...
Cached Medicine News:Health News:Excess Weight Can Affect Individuals as They Age 2Health News:Animals Can give us a second chance at life 2Health News:Predictors for Type 2 Diabetes 2Health News:Changing Partners may put Expectant Mothers at Risk 2
Superior comfort and flexibility are achieved through the revolutionary air pocket technology in the dimpled, ultra-thin SoftFlex skin barrier along with a discreet pouch shape and size....
Inquire...
Inquire...
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Medicine Products: